Novartis India (BOM:500672) Cyclically Adjusted Revenue per Share: ₹210.06 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:500672 Novartis India Ltd BOM:500672
60 GF Score
Price ₹1,482.45
GF Value ₹1,041.35
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Novartis India Cyclically Adjusted Revenue per Share?

Novartis India BOM:500672 -3.21% 60 Cyclically Adjusted Revenue per Share is ₹210.06 as of Jun. 2026. GuruFocus rates BOM:500672 with a GF Score™ of 60/100 and a GF Value™ of ₹1,041.35 (Significantly Overvalued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Novartis India's adjusted revenue per share for the three months ended in Jun. 2026 was ₹42.059. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹210.06 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Novartis India's average Cyclically Adjusted Revenue Growth Rate was -3.80% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -7.40% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -7.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Novartis India was -6.20% per year. The lowest was -7.90% per year. And the median was -7.40% per year.

As of today (2026-08-21), Novartis India's current stock price is ₹1482.45. Novartis India's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ₹210.06. Novartis India's Cyclically Adjusted PS Ratio of today is 7.06.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Novartis India was 7.84. The lowest was 1.82. And the median was 2.79.


Novartis India  (BOM:500672) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Novartis India's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1482.45/210.06
=7.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Novartis India was 7.84. The lowest was 1.82. And the median was 2.79.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Novartis India Cyclically Adjusted Revenue per Share Related Terms


Novartis India Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Novartis India's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novartis India Cyclically Adjusted Revenue per Share Chart

Novartis India Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 285.06 266.60 245.81 222.74 211.84

Novartis India Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 218.26 214.19 209.44 211.84 210.06

BOM:500672 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Novartis India's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novartis India Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novartis India's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Novartis India's Cyclically Adjusted PS Ratio falls into.


BOM:500672
60GF Score
Novartis India Ltd BOM:500672
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novartis India Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Novartis India's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=42.059/167.3573*167.3573
=42.059

Current CPI (Jun. 2026) = 167.3573.

Novartis India Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 55.411 105.961 87.517
201612 60.175 105.196 95.733
201703 51.501 105.196 81.933
201706 40.829 107.109 63.795
201709 59.562 109.021 91.433
201712 55.477 109.404 84.864
201803 45.450 109.786 69.284
201806 55.931 111.317 84.089
201809 43.223 115.142 62.824
201812 54.902 115.142 79.799
201903 28.351 118.202 40.141
201906 44.277 120.880 61.301
201909 47.609 123.175 64.686
201912 47.562 126.235 63.056
202003 26.846 124.705 36.028
202006 37.489 127.000 49.402
202009 38.867 130.118 49.991
202012 38.300 130.889 48.971
202103 33.752 131.771 42.867
202106 39.838 134.084 49.724
202109 42.269 135.847 52.073
202112 40.052 138.161 48.516
202203 34.819 138.822 41.976
202206 48.963 142.347 57.566
202209 41.106 144.661 47.555
202212 32.447 145.763 37.254
202303 26.903 146.865 30.657
202306 36.714 150.280 40.886
202309 31.897 151.492 35.237
202312 34.236 152.924 37.467
202403 32.448 153.035 35.485
202406 37.361 155.789 40.135
202409 35.292 157.882 37.410
202412 37.675 158.323 39.825
202503 33.982 157.552 36.097
202506 35.470 159.755 37.158
202509 36.587 162.289 37.730
202512 34.808 163.281 35.677
202603 36.687 164.272 37.376
202606 42.059 167.357 42.059

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹210.06 mean?
Novartis India (BOM:500672) has a Cyclically Adjusted Revenue per Share of ₹210.06 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Novartis India and its competitors.
Is Novartis India's Cyclically Adjusted Revenue per Share too high?
Novartis India's current Cyclically Adjusted Revenue per Share is ₹210.06. Overall, Novartis India has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Novartis India's Cyclically Adjusted Revenue per Share compare to ZTS?
Novartis India's Cyclically Adjusted Revenue per Share of ₹210.06 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Novartis India and its competitors. Novartis India's current Cyclically Adjusted Revenue per Share is ₹210.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novartis India stock overvalued right now?
Based on GuruFocus' analysis, Novartis India (BOM:500672) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹1,041.35, compared to a current price of ₹1,482.45 — trading 42.4% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹210.06. Novartis India's overall GF Score™ is 60/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Novartis India (BOM:500672), the current Cyclically Adjusted Revenue per Share is ₹210.06 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novartis India (BOM:500672) Overvalued in 2026?

Based on GuruFocus' analysis, Novartis India stock appears to be overvalued. The current stock price of ₹1,482.45 is trading 42.4% above its estimated GF Value™ of ₹1,041.35. GuruFocus considers Novartis India to be Significantly Overvalued.

Key valuation signals for BOM:500672:

  • Cyclically Adjusted Revenue per Share: ₹210.06
  • GF Value™: ₹1,041.35 vs. price of ₹1,482.45 (42.4% above fair value)
  • GF Score™: 60/100 with 7 warning signs

No single metric tells the full story. See the BOM:500672 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Novartis India Business Description

Other Exchanges NOVARTIND:India
Address Inspire BKC, Part of 601 & 701, Bandra Kurla Complex, Bandra (East), Mumbai, MH, IND, 400 051
Novartis India Ltd is an Indian-based pharmaceutical company. The company is engaged in the trading of Drugs and Pharmaceuticals. It derives revenue from operations in India. The company operates in a single business segment, namely Pharmaceutical Business. Its Pharmaceutical business focuses on Bone and Pain, Transplantation Immunology, and Neurosciences.
60GF Score

Get the complete analysis for BOM:500672

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,482.45
Price
₹1,041.35
GF Value